Conventional vaccines, also known as traditional or inactivated vaccines, represent a widely used and effective approach to immunization. These vaccines utilize either weakened or killed forms of the targeted pathogen, such as viruses or bacteria, to stimulate an immune response without causing the disease. Inactivated vaccines typically involve using heat, chemicals, or radiation to deactivate the infectious agent while preserving its immunogenic properties. Live attenuated vaccines use weakened forms of the pathogen, rendering them less virulent but still capable of eliciting a robust immune response. Examples of conventional vaccines include those against diseases like influenza, polio, hepatitis A and B, and pertussis. These vaccines have been instrumental in controlling and preventing a range of infectious diseases, contributing significantly to public health. Conventional vaccines have some limitations, such as the need for cold storage for certain types and the potential for reversion to virulence in live attenuated vaccines. However, ongoing research and advancements continue to optimize these vaccines and explore new technologies for vaccine development. They remain a cornerstone of global vaccination efforts, providing essential protection against a variety of infectious diseases.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy